AZRX - AzurRx adds two new trial sites in Europe for phase 2b OPTION 2 extension study

AzurRx BioPharma ([[AZRX]] -7.6%) announces the activation of two additional clinical trial sites in Poland for the extension arm of the Phase 2b OPTION 2 study investigating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency ((EPI)) in patients with cystic fibrosis ((CF)).Additional sites were added in Europe to minimize any potential patient enrollment delays during the ongoing COVID-19 pandemic, the company said.The two sites in Poland, as well as the active clinical trial sites in the U.S., are actively enrolling patients, and AzurRx expects to report top-line results from the trial during Q1 2021.OPTION 2 is a Phase 2b, open-label, multi-center, crossover clinical trial designed to investigate the safety, tolerability, and efficacy of MS1819 in a head-to-head comparison against the current standard of care, porcine pancreatic enzyme replacement therapy ((PERT)) pills. The primary efficacy endpoint is the coefficient of fat absorption ((CFA)).The extension arm of the Phase 2b OPTION 2 trial is designed to

For further details see:

AzurRx adds two new trial sites in Europe for phase 2b OPTION 2 extension study